By simultaneously combining three kinds of tumor-associated mRNAs (i.e., C-myc mRNA, TK1 mRNA, and GT mRNA) in breast cancer cells, the triple-interlocked nanomodule could be unlocked for precise drug release. Here, MYC is linked to neoplasm.